Mesoblast Limited reported net revenues of US$30 million for the second fiscal quarter ended December 31, 2025, driven by Ryoncil® sales, which saw gross sales of US$35 million—a 60% increase compared to the previous quarter. The company also announced the establishment of a new non-dilutive credit line totaling US$125 million at a fixed interest rate of 8.00% per annum, replacing existing debt facilities and featuring a five-year interest-only period. As of December 31, 2025, Mesoblast held US$130 million in cash, with a net operating cash spend of US$16 million for the quarter. The company expects reduced net cash spend for the remainder of the fiscal period due to projected revenue and expense controls. Operational highlights included progress in the confirmatory Phase 3 trial MSB-DR004 for rexlemestrocel-L and positive FDA feedback regarding a potential Biologics License Application filing for rexlemestrocel-L in chronic discogenic low back pain patients.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mesoblast Limited published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9644899) on January 28, 2026, and is solely responsible for the information contained therein.